plinabulin (Pending FDA Approval)

Brand and Other Names:

Dosing & Uses

Chemotherapy-Induced Neutropenia

Pending FDA approval for using in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN)

Next:

Pharmacology

Mechanism of Action

First-in-class selective immunomodulating microtubule-binding agent (SIMBA)

Binds to colchicine-binding site of tubulin, which releases the immune defense protein, GEF-H1, that activates a signaling transduction pathway, leading to dendritic cell maturation and its innate and adaptive immune activity

Has the potential to directly kill cancer cells; also has the potential to increase maturation of dendritic cells, resulting in increased antigen presentation and T-cell activation, which potentially contributes to its anticancer effects

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.